



## Novel Therapies for Pediatric Acute Myeloid Leukemia

Guest Editor:

**Dr. Sarah K. Tasian**

Children's Hospital of  
Philadelphia, Division of  
Oncology and Center for  
Childhood Cancer Research,  
Philadelphia, United States

Deadline for manuscript  
submissions:

**closed (28 February 2021)**

### Message from the Guest Editor

Dear Colleagues,

Approximately two-thirds of children and adolescents with acute myeloid leukemia (AML) are cured with modern risk-adapted therapy comprised of multi-agent chemotherapy and often hematopoietic stem cell transplantation. Current pediatric regimens are maximally intensive and are associated with both short- and long-term toxicity. Chemotherapy resistance nonetheless remains a major barrier to cure, highlighting a need for new therapies, potentially with alternative mechanisms of action. Recent advances in the molecular genetic characterization of pediatric AML and measurable residual disease (MRD) quantification and the correlation of these data with clinical outcomes have further refined risk stratification and recommended treatment protocols. Finally, increasing the availability of promising novel chemotherapies, small molecule inhibitors, and immunotherapies together with global collaboration has facilitated the development of innovative early-phase clinical trials specifically for children with high-risk or relapsed/refractory AML.

Dr. Sarah K. Tasian

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)